StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Equities research analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

NASDAQ:TXMD opened at $0.86 on Thursday. The stock has a 50 day simple moving average of $1.33 and a 200 day simple moving average of $1.58. TherapeuticsMD has a 1-year low of $0.70 and a 1-year high of $2.75.

Institutional Trading of TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP raised its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.